Monday, 17 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Move to Shore Up Trust as Leadership Shifts and AI-Adjacent Markets Wobble
Major AI and media platforms are converging on trust and accountability measures — Anthropic's Claude adding watermarks, Spotify labeling AI artists — just as OpenAI loses special-projects lead Brad Lightcap and Meta's Zuckerberg publishes a defensive manifesto on AI's societal role. In parallel, AI-adjacent financial dynamics are surfacing real stress: Wall Street firms are paying for privileged early access to Trump's Truth Social posts for trading edge, while Trump Media itself reports a $238M loss driven by falling crypto holdings, highlighting how information asymmetry and speculative digital assets are becoming entangled with AI-era platforms.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,809
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,809 facts checked against source5,205 source documents archived
Work with this data → vianewsagency.com

LNA SANTE, CEGEDIM, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Healthcare Sector.

Loading stream...

(vianews) - lna sante (lna.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.

financial asset price forward dividend yield return on equity
lna sante (lna.pa) €19.48 2.54% 9.08%
cegedim (cgm.pa) €17.84 2.25% 3.08%
medistim (medi.ol) kr224.00 2.25% 32.37%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. lna sante (lna.pa)

2.54% forward dividend yield and 9.08% return on equity

lna santé sa engages in the management and operation of health establishments. the company operates retirement homes, medical and rehabilitation care, home hospital, mental health clinic, and health center. lna santé sa was founded in 1990 and is based in vertou, france.

earnings per share

as for profitability, lna sante has a trailing twelve months eps of €2.28.

pe ratio

lna sante has a trailing twelve months price to earnings ratio of 8.54. meaning, the purchaser of the share is investing €8.54 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.08%.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on jul 6, 2023, the estimated forward annual dividend rate is 0.5 and the estimated forward annual dividend yield is 2.54%.

moving average

lna sante's value is way under its 50-day moving average of €25.38 and way below its 200-day moving average of €28.85.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, lna sante's stock is considered to be oversold (<=20).

more news about lna sante.

2. cegedim (cgm.pa)

2.25% forward dividend yield and 3.08% return on equity

cegedim sa operates as a technology and services company in the field of digital data flow management for healthcare ecosystem and b2b, and business software publisher for healthcare and insurance professionals in france, other european countries, and internationally. it operates in two segments, health insurance, hr and e-services; and healthcare professionals. the health insurance, hr and e-services segment markets various products and services to insurance companies, mutual insurers, personal protection insurers, and insurance brokers, as well as engages in the interactions between these entities and healthcare professionals. this segment also provides solutions for hosting, hr and payroll management outsourcing, electronic data exchange, and data processing services. the healthcare professionals division sells management software, databases, and solutions to doctors, allied health professionals, pharmacists, and healthcare facilities. the company was incorporated in 1969 and is headquartered in boulogne-billancourt, france. cegedim sa is a subsidiary of fcb sa.

earnings per share

as for profitability, cegedim has a trailing twelve months eps of €0.8.

pe ratio

cegedim has a trailing twelve months price to earnings ratio of 22.3. meaning, the purchaser of the share is investing €22.3 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.08%.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on jun 29, 2022, the estimated forward annual dividend rate is 0.5 and the estimated forward annual dividend yield is 2.25%.

moving average

cegedim's worth is under its 50-day moving average of €18.21 and below its 200-day moving average of €19.37.

volatility

cegedim's last week, last month's, and last quarter's current intraday variation average was a negative 0.04%, a negative 0.23%, and a positive 1.53%.

cegedim's highest amplitude of average volatility was 1.09% (last week), 1.05% (last month), and 1.53% (last quarter).

volume

today's last reported volume for cegedim is 272 which is 95.05% below its average volume of 5501.

more news about cegedim.

3. medistim (medi.ol)

2.25% forward dividend yield and 32.37% return on equity

medistim asa develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the united states, europe, asia, and internationally. it offers miraq cardiac, a system that combines ultrasound imaging and transit time flow measurement (ttfm) in a single system for cardiac surgery; miraq vascular, a system that combines ultrasound imaging and transit ttfm in a single system for vascular surgery; and imaging probes for intraoperative use. the company also provides various flow probes, such as quickfit ttfm probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; vascular ttfm probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. in addition, it distributes and sells third party medical equipment. the company was incorporated in 1984 and is headquartered in oslo, norway.

earnings per share

as for profitability, medistim has a trailing twelve months eps of kr6.42.

pe ratio

medistim has a trailing twelve months price to earnings ratio of 34.89. meaning, the purchaser of the share is investing kr34.89 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 32.37%.

volume

today's last reported volume for medistim is 1376 which is 79.86% below its average volume of 6833.

earnings before interest, taxes, depreciation, and amortization

medistim's ebitda is 6.72.

volatility

medistim's last week, last month's, and last quarter's current intraday variation average was 3.54%, 0.45%, and 1.95%.

medistim's highest amplitude of average volatility was 3.54% (last week), 1.73% (last month), and 1.95% (last quarter).

more news about medistim.